Atripla Co-pay Program to Cover More People

POZ - POZ Magazine - POZ.com - Treatment News: "Gilead Sciences and Bristol-Myers Squibb have announced that the co-payment assistance program for Atripla (containing efavirenz, tenofovir and emtricitabine) has been revised and will essentially benefit all people living with HIV with private health insurance who pay any out-of-pocket co-payment fees. The greatly enhanced co-payment program went into effect July 1."